Clal Biotechnology Industries Ltd.
Tel Aviv Stock ExchangeTotal Valuation
Clal Biotechnology Industries Ltd. carries a market capitalization of 41.25M, placing it among publicly traded companies globally. Its enterprise value stands at 9.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 41.25M |
| Enterprise Value | 9.90B |
Share Statistics
Clal Biotechnology Industries Ltd. currently has 156.85M shares outstanding.
| Shares Outstanding | 156.85M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 327.75, and the price-to-book ratio stands at -7.59.
| PE Ratio | N/A |
| PS Ratio | 327.75 |
| PB Ratio | -7.59 |
| P/TBV Ratio | 68.02 |
| P/FCF Ratio | -170.63 |
| P/OCF Ratio | -166.95 |
Enterprise Valuation
| EV / Sales | 329.17 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Clal Biotechnology Industries Ltd. maintains a current ratio of 5.71, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.35, indicating elevated leverage, while an interest coverage ratio of -6.37 demonstrates limited ability to service its debt obligations.
| Current Ratio | 5.71 |
| Quick Ratio | 4.42 |
| Debt / Equity | 25.35 |
| Debt / EBITDA | -0.83 |
| Interest Coverage | -6.37 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -19.67 |
| Return on Invested Capital (ROIC) | -16.65 |
| Return on Capital Employed (ROCE) | 1.83 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 16.25 |
Taxes
Over the trailing twelve months, Clal Biotechnology Industries Ltd. has paid 25,000.00 in income taxes, reflecting an effective tax rate of 0.15.
| Income Tax | 25,000.00 |
| Effective Tax Rate | 0.15 |
Stock Price Statistics
Clal Biotechnology Industries Ltd.'s stock has declined approximately -14.05229% over the past 52 weeks. The 50-day moving average sits at 29.41, while the 200-day moving average is 31.48.
| Beta (5Y) | N/A |
| 52-Week Price Change | -14.05229% |
| 50-Day Moving Average | 29.41 |
| 200-Day Moving Average | 31.48 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Clal Biotechnology Industries Ltd. generated 30.07M in revenue and converted that into -61.74M in net income, yielding earnings per share of -0.48. EBITDA reached -44.32M, while operating income came in at -44.32M.
| Revenue | 30.07M |
| Gross Profit | -544,000.00 |
| Operating Income | -44.32M |
| Pretax Income | 17.20M |
| Net Income | -61.74M |
| EBITDA | -44.32M |
| EBIT | -44.32M |
| Earnings Per Share (EPS) | -0.48 |
Balance Sheet
Clal Biotechnology Industries Ltd. holds 12.89M in cash and equivalents against 36.73M in total debt, resulting in a net debt position of 19.95M. Total book value stands at -1.30B, with working capital of 13.73M providing operational flexibility.
| Cash & Cash Equivalents | 12.89M |
| Total Debt | 36.73M |
| Net Debt | 19.95M |
| Equity (Book Value) | -1.30B |
| Book Value Per Share | -8.28 |
| Working Capital | 13.73M |
Cash Flow
Clal Biotechnology Industries Ltd. produced -59.04M in operating cash flow over the past twelve months. After subtracting -1.27M in capital expenditures, free cash flow totaled -60.31M - equivalent to -0.38 per share.
| Operating Cash Flow | -59.04M |
| Capital Expenditures | -1.27M |
| Free Cash Flow | -60.31M |
| FCF Per Share | -0.38 |
Margins
Clal Biotechnology Industries Ltd. operates with a gross margin of -0.85, reflecting its pricing power and cost economics. The operating margin of -147.38 and net profit margin of -205.30 provide insight into operational efficiency.
| Gross Margin | -0.85 |
| Operating Margin | -147.38 |
| Pretax Margin | 57.18 |
| Profit Margin | -205.30 |
| EBITDA Margin | -147.38 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.20 |
| FCF Yield | -0.59 |
Stock Splits
Clal Biotechnology Industries Ltd.'s most recent stock split took place on April 22, 2013 with a 250:257 split ratio.
| Last Split Date | 4/22/2013 |
| Split Ratio | 250:257 |
Scores
Clal Biotechnology Industries Ltd. posts an Altman Z-Score of 145.96, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 145.96 |